Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

#ESMO21 Highlights on MFS analysis from comb. treatments in high-risk adv. prostate cancer: STAMPEDE

Gerhardt Attard reports on key results from ESMO Congress 2021 on LBA4_PR - Abiraterone acetate and prednisolone (AAP) or AAP and enzalutamide (enza) added to androgen deprivation therapy (ADT) for men with high-risk locally advanced prostate cancer (PCa): metastases-free survival (MFS) results from STAMPEDE (NCT00268476)

19 Sep 2021  Presidential symposium 2

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.